An interventional study of Synthetic Hybrid-Scale Fiber Matrix and Standard of Care in Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Acera Surgical, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.
Among the 12 studies in Diabetic Foot by Solventum, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 12th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2021.
This study's enrollment of 48 is below the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 48 across the 9 interventional studies, 135 across the 3 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acera Surgical, Inc., one of the names counted as Solventum. Under that name alone:
Acera Surgical, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetic Foot by Solventum, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care.
In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)
Inclusion Criteria for Participants with Diabetic Foot Ulcers:
Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:
Exclusion Criteria for Participants with Diabetic Foot Ulcers:
Inclusion Criteria for Participants with Venous Leg Ulcers:
Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:
Exclusion Criteria for Participants with Venous Leg Ulcers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
Device: Synthetic Hybrid-Scale Fiber Matrix
Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
Device: Standard of Care
Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
Device: Synthetic Hybrid-Scale Fiber Matrix
Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
Device: Living Cellular Skin Substitute
A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
Also known as: Restrata
To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
Also known as: Apligraf
For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound
The number of wounds in each treatment arm that achieved 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization
Time frame: 12 weeks
For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound
The number of wounds in each treatment arm with 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization
Time frame: 16 weeks
Percentage Change in Wound Area
Wound area measurements will be made via a three-dimensional high resolution photo of the wound with automated measurements. Mean percent wound change will be calculated for each treatment arm/group with Week 1 as the baseline value. Change is calculated using the 2-week follow up visit after wound closure for wounds that achieved closure, or for wounds that did not achieve closure, the Week 12 wound area for DFUs and Week 16 wound area for VLUs.
Time frame: Weekly assessments for 12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first.
Time to 100 Percent Epithelialization
The number of weeks from initial application of study product until 100 percent epithelialization is first identified.
Time frame: 12 weeks for DFU wounds (16 weeks for VLU wounds), or until 100 percent epithelialization, whichever occurs first.
Total Number of Product Applications
The number of study applications including the initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first
Time frame: Initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first
| Milestone | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) |
|---|---|---|---|---|
| Started | 8 | 10 | 14 | 16 |
| Completed | 2 | 6 | 11 | 13 |
| Not completed | 6 | 4 | 3 | 3 |
| Withdrew: Study closure | 5 | 4 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
The number of wounds in each treatment arm that achieved 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization
| wounds | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care |
|---|---|---|
| For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound | 2 | 1 |
The number of wounds in each treatment arm with 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization
| wounds | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) |
|---|---|---|
| For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound | 1 | 4 |
Wound area measurements will be made via a three-dimensional high resolution photo of the wound with automated measurements. Mean percent wound change will be calculated for each treatment arm/group with Week 1 as the baseline value. Change is calculated using the 2-week follow up visit after wound closure for wounds that achieved closure, or for wounds that did not achieve closure, the Week 12 wound area for DFUs and Week 16 wound area for VLUs.
| Percentage change | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) |
|---|---|---|---|---|
| Percentage Change in Wound Area | -100 ± 0 | -64.9 ± 53.2 | -14.2 ± 77.4 | -52.7 ± 48.8 |
The number of weeks from initial application of study product until 100 percent epithelialization is first identified.
| Weeks | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care (SOC) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata) |
|---|---|---|---|---|
| Time to 100 Percent Epithelialization | 6 ± 0 | 10.8 ± 3.6 | 6 ± 0 | 9.5 ± 1.0 |
The number of study applications including the initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first
| Number of applications | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care (SOC) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata) |
|---|---|---|---|---|
| Total Number of Product Applications | 7.7 ± 2.8 | 7.1 ± 2.3 | 8.9 ± 4.0 | 4.1 ± 1.5 |
Collected over 2 weeks after healing OR 2 weeks after 12-14 weeks of treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Diabetic Foot Ulcer Participants Assigned to Standard of Care | 0/10 (0%) | 3/10 (30%) | 4/10 (40%) |
| Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | 0/14 (0%) | 1/14 (7.1%) | 8/14 (57.1%) |
| Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Event | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) |
|---|---|---|---|---|
| AmputationInfections and infestations | 0/8 | 1/10 | 0/14 | 0/16 |
| AtherectomyInvestigations | 0/8 | 1/10 | 0/14 | 0/16 |
| Pain near woundSkin and subcutaneous tissue disorders | 0/8 | 1/10 | 0/14 | 0/16 |
| FallInjury, poisoning and procedural complications | 0/8 | 0/10 | 1/14 | 0/16 |
| Event | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) |
|---|---|---|---|---|
| BlisterSkin and subcutaneous tissue disorders | 1/8 | 0/10 | 0/14 | 0/16 |
| Arteriovenous fistulaVascular disorders | 1/8 | 0/10 | 0/14 | 0/16 |
| Facial skin infectionSkin and subcutaneous tissue disorders | 1/8 | 0/10 | 0/14 | 0/16 |
| Skin lesion excisionSkin and subcutaneous tissue disorders | 1/8 | 0/10 | 0/14 | 0/16 |
| skin ulcerSkin and subcutaneous tissue disorders | 0/8 | 1/10 | 1/14 | 1/16 |
| HeadacheGeneral disorders | 0/8 | 1/10 | 0/14 | 0/16 |
| Joint injuryInjury, poisoning and procedural complications | 0/8 | 1/10 | 0/14 | 0/16 |
| limb injuryInjury, poisoning and procedural complications | 0/8 | 1/10 | 0/14 | 0/16 |
| Wound infection staphylococcalInfections and infestations | 0/8 | 0/10 | 1/14 | 1/16 |
| influenza like illnessGeneral disorders | 0/8 | 0/10 | 1/14 | 0/16 |
| Age, Continuous(years) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Total |
|---|---|---|---|---|---|
| Mean | 67 ± 12.6 | 53 ± 14.5 | 59 ± 10.4 | 73 ± 12.2 | 64 ± 14.7 |
| Sex: Female, Male(Participants) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 7 | 9 | 21 |
| Male | 6 | 7 | 7 | 7 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 1 | 7 | 12 |
| Not Hispanic or Latino | 7 | 7 | 13 | 9 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 3 | 2 | 2 | 7 |
| White | 8 | 7 | 11 | 14 | 40 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Wound area at baseline in cm^2(cm^2) | Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Diabetic Foot Ulcer Participants Assigned to Standard of Care | Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) | Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) | Total |
|---|---|---|---|---|---|
| Mean | 3.0 ± 1.2 | 5.0 ± 4.4 | 17.7 ± 13.9 | 14.4 ± 12.2 | 11.6 ± 12.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Jul 2024, 35 months.
Results were first posted in Feb 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.